SCHEMBL18908256

SCHEMBL18908256

CCCCOCCCC(C(=O)O)c1cc(F)ccc1OC

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.40
PPARA Q07869 3/20 0.38
PPARD Q03181 2/20 0.38
PPARG P37231 1/20 0.38
FAAH O00519 2/20 0.38
PTGES O14684 1/20 0.37
RARA P10276 1/20 0.37
RARB P10826 1/20 0.37
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
CYSLTR2 Q9NS75 1/20 0.36
CYSLTR1 Q9Y271 1/20 0.36
LPAR1 Q92633 1/20 0.36
LPAR5 Q9H1C0 1/20 0.36
TSHR P16473 1/20 0.36
FFAR1 O14842 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
PLA2G4B P0C869 1/20 0.35
TSPO P30536 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18908257 0.85 FFAR1 (0.41) NPSR1FFAR1FFAR4
SCHEMBL18908255 0.81 NPSR1 (0.36) NPSR1FAAHTAS1R3TAS1R1TSHR
SCHEMBL21807064 0.75 USP9X (0.50) NPSR1FFAR1FFAR4
SCHEMBL10767353 0.72 AKR1C3 (0.48) PPARAPPARGCYSLTR2CYSLTR1TSPO
SCHEMBL8122362 0.71 AKR1C3 (0.47) PPARAPPARGCYSLTR2CYSLTR1
SCHEMBL8428047 0.70 PLA2G4B (0.44) PPARAPPARGPTGESCYSLTR2CYSLTR1
SCHEMBL20817253 0.70 NPSR1 (0.47) NPSR1TSHRFFAR1FFAR4
SCHEMBL22457320 0.70 PTGS2 (0.60) TSHRFFAR1FFAR4
SCHEMBL12500530 0.70 MAPT (0.42) PPARDPPARGPTGESRARARARB
SCHEMBL31114370 0.70 POLB (0.44) NPSR1PPARATAS1R3TAS1R1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166584-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2017-06-15 US disclosed
WO-2017091617-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC (US) 2017-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166584-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT1 NPSR1 4556/4885PPARA 412/4885PPARD 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.